Other Events ·
On June 16, 2026, stockholders approved the Third Amended and Restated 2021 Stock Incentive Plan, increasing the…
INMBInmune Bio, Inc.
On June 16, 2026, stockholders approved the Third Amended and Restated 2021 Stock Incentive Plan, increasing the number of issuable common shares from 6,500,000 to 9,158,525. The approval includes an evergreen provision from 2027 through 2031 that automatically increases reserved shares annually by the lesser of 10% of outstanding common stock as of December 31 of the preceding year or a smaller amount determined by the board. Stockholders also elected the board of directors and ratified CBIZ CPAs P.C. as the independent auditor for the fiscal year ending December 31, 2026. Inmune Bio is a biotechnology company developing therapies for neurodegenerative diseases.